Chan et al[9] reported that 26 patients with myeloid tumor bearing PDGFRB fusion achieve durable long term remissions with imatinib, with a 10-year overall survival of 90% and a 6-year PFS of 88%. This evidence concerns the gene PDGFRB and myeloid neoplasm.